Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives $20.25 Consensus Target Price from Brokerages

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) have earned a consensus rating of “Hold” from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. Thirteen investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $20.25.

Several research firms have commented on FUSN. Raymond James reiterated a “market perform” rating on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. SVB Leerink reissued a “market perform” rating and issued a $21.00 price target (up from $17.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Truist Financial restated a “hold” rating and set a $21.00 price objective (up previously from $11.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Jonestrading reiterated a “hold” rating on shares of Fusion Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Leerink Partnrs downgraded Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 19th.

Fusion Pharmaceuticals Stock Performance

Fusion Pharmaceuticals stock opened at $21.55 on Friday. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -15.18 and a beta of -0.69. The firm has a 50-day moving average of $21.49 and a 200-day moving average of $16.03. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.64 and a quick ratio of 10.64. Fusion Pharmaceuticals has a one year low of $2.31 and a one year high of $21.60.

Fusion Pharmaceuticals (NASDAQ:FUSN) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 48.74%. On average, equities analysts expect that Fusion Pharmaceuticals will post -1.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in Fusion Pharmaceuticals by 883.0% during the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock worth $28,000 after buying an additional 2,649 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Fusion Pharmaceuticals by 2,064.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock valued at $29,000 after buying an additional 2,869 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Fusion Pharmaceuticals by 66.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 13,920 shares of the company’s stock worth $297,000 after acquiring an additional 5,544 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of Fusion Pharmaceuticals in the fourth quarter worth approximately $64,000. Finally, Bluefin Capital Management LLC bought a new stake in Fusion Pharmaceuticals in the first quarter valued at approximately $213,000. Institutional investors and hedge funds own 72.85% of the company’s stock.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.